Riskpilot← Back to searchSign inGet full accessLYTIX BIOPHARMA ASA
ASAActiveOrg 985889635Sandakerveien 138, 0484 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20036 employeeswww.lytixbiopharma.com
Revenue 2024
NOK 11,1M
+179% vs 2023
EBITDA margin
-853.1%
+1% vs 2023
Equity ratio
73.6%
Financial strength
Net profit 2024
NOK -94,3M
-7% vs 2023
| Revenue | NOK 11,1M | +179% |
| EBITDA | NOK -95M | +1% |
| Net profit | NOK -94,3M | -7% |
| Total assets | NOK 146,5M | +129% |
| Equity | NOK 107,9M | +110% |
| Employees | 6 | — |
Legal name
LYTIX BIOPHARMA ASA
Org number
985889635
Legal form
Allmennaksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
25. august 2003
Share capital
NOK 7 690 000
Employees
6 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Utvikling, markedsføring og salg av farmasøytiske og bioteknologiske produkter, samt dertil hørende virksomhet. Selskapet kan ha eierinteresser i foretak innen samme eller tilstøtende bransjer.
Address
Sandakerveien 138, 0484 Oslo
Email
post@lytixbiopharma.com
Website
www.lytixbiopharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 6 678 | 25 827 | 17 273 | 3 991 | 11 134 |
| Staff expenses | −23 416 | −31 605 | −21 133 | −0 | −0 |
| EBITDA | −42 372 | −48 016 | −65 666 | −95 822 | −94 981 |
| Depreciation & amort. | −0 | −0 | −30 | −962 | −915 |
| EBIT | −42 372 | −48 016 | −65 696 | −96 785 | −95 896 |
| Net financials | 284 | −32 | 9 689 | 8 887 | 1 631 |
| Profit before tax | −42 088 | −48 048 | −56 007 | −87 897 | −94 265 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −42 088 | −48 048 | −56 007 | −87 897 | −94 265 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 32 617 | 202 962 | 152 017 | 63 874 | 146 535 |
| Equity | 19 889 | 189 624 | 135 126 | 51 319 | 107 894 |
| Long-term debt | 0 | 0 | 0 | 41 | 1 878 |
| Short-term debt | 12 728 | 13 338 | 16 891 | 12 514 | 36 764 |
| Total debt | 12 728 | 13 338 | 16 891 | 12 555 | 38 642 |
EBITDA margin
-853.1%
This company
15.8%
Market median
-5499% vs market
20202024
Equity ratio
73.6%
This company
38.2%
Market median
+93% vs market
20202024
Return on equity
-87.4%
This company
18.4%
Market median
-575% vs market
20202024
Net profit margin
-846.6%
This company
8.1%
Market median
-10552% vs market
20202024
Asset turnover
0.08×
This company
1.12×
Market median
-93% vs market
20202024
Debt / equity
0.36×
This company
0.62×
Market median
+42% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
ØR Chief Executive Officer | Chief Executive Officer | 2019 |
| Name | Role | Member since |
|---|---|---|
| Current (7) | ||
| Board of Directors | 2021 | |
| Board of Directors | 2025 | |
| Board of Directors | 2021 | |
| Board of Directors | 2026 | |
| Board of Directors | 2025 | |
| Chairman | 2025 | |
| Board of Directors | 2021 | |
| Former (6) | ||
| Chairman | 2021 – 2023 | |
| Board of Directors | 2021 – 2025 | |
| Board of Directors | 2020 – 2021 | |
| Board of Directors | 2021 – 2025 | |
| Chairman | 2023 – 2025 | |
| Board of Directors | 2020 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 9.21% | 9.21% | 2022 | |
| Company | 8.94% | 8.94% | 2024 | |
Citibank, N.A. | Company | 7.18% | 7.18% | 2024 |
| Company | 6.58% | 6.58% | 2024 | |
| Company | 6.54% | 6.54% | 2024 | |
Skandinaviska Enskilda Banken Ab | Company | 3.86% | 3.86% | 2024 |
| Company | 3.58% | 3.58% | 2024 | |
| Company | 3.35% | 3.35% | 2024 | |
| Company | 2.96% | 2.96% | 2024 | |
| Individual | 2.8% | 2.8% | 2022 | |
| Company | 2.65% | 2.65% | 2024 | |
| Individual | 2.17% | 2.17% | 2022 | |
| Company | 2.13% | 2.13% | 2024 | |
| Company | 2.04% | 2.04% | 2024 | |
| Company | 1.94% | 1.94% | 2024 | |
| Company | 1.92% | 1.92% | 2024 | |
| Company | 1.75% | 1.75% | 2024 | |
| Company | 1.48% | 1.48% | 2024 | |
| Company | 1.4% | 1.4% | 2024 | |
| Company | 1.32% | 1.32% | 2024 | |
| Company | 1.08% | 1.08% | 2024 | |
| Company | 1.02% | 1.02% | 2024 | |
| Company | 1.01% | 1.01% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of LYTIX BIOPHARMA ASA also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Øystein Rekdal | Chief Executive Officer | 0 companies |
| Kjetil Hestdal | Board of Directors | 0 companies |
| Julie Helene Madeleine Dehaene | Board of Directors | 0 companies |
| Helena Marie-Louise Fjällskog | Board of Directors | 0 companies |
| Gert Wilhelm Munthe | Chairman | 0 companies |
| Darlene M Deptula-Hicks | Board of Directors | 0 companies |
| Jayson Michael Rieger | Board of Directors | 0 companies |
| Debasish Francois Roychowdhury | Board of Directors | 0 companies |
| Evelina Wanda Matilda Vägesjö | Board of Directors | 0 companies |
| Claus Asbjørn Andersson | Board of Directors | 0 companies |
| Marie Ann Roskrow | Chairman | 0 companies |
| Eric Michel Falcand | Chairman | 0 companies |
| Per Erik Sørensen | Board of Directors | 0 companies |
| Brynjar Kristian Forbergskog | Board of Directors | 0 companies |